1 Correction to: Targeted Oncology (2020) 15:599–611 https://doi.org/10.1007/s11523-020-00748-4
Page 608, 4 Discussion, right column, second paragraph: The sentence, which previously read:
“Equivalence in clinical efficacy of ABP 798 with respect to rituximab RP in patients with CD20-positive B cell NHL was further supported by the results of efficacy assessment at week 12, with a two-sided 90% CI (− 0.3 to 11.2%)”.
Anzeige
should read:
“Equivalence in clinical efficacy of ABP 798 with respect to rituximab RP in patients with CD20-positive B-cell NHL was further supported by the results of efficacy assessment at week 12, with a two-sided 90% CI (− 9.3 to 11.2%)”.
The original article has been updated.
Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.